Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
09 2019
Historique:
pubmed: 9 8 2019
medline: 13 3 2020
entrez: 9 8 2019
Statut: ppublish

Résumé

Background and Purpose- We compared the 1-year safety and effectiveness of rivaroxaban 15 mg (R15) or rivaroxaban 20 mg (R20) to vitamin K antagonists (VKAs) in patients with nonvalvular atrial fibrillation. Methods- New user cohort study of patients dispensed R15 or R20 versus VKA in 2013 or 2014 for nonvalvular atrial fibrillation, followed 1 year in the French Système National des Données de Santé (66 million people). R15 and R20 users were matched 1:1 with VKA users on sex, age, date of first drug dispensing, and high-dimensional propensity score. Hazard ratios (95% CIs) for stroke and systemic embolism, major bleeding, and death were computed using Cox proportional hazards or models by Fine and Gray during exposure. Results- In 31 171 matched R20 and VKA, mean age, 71; 62% men; 76% with CHA

Identifiants

pubmed: 31390972
doi: 10.1161/STROKEAHA.119.025824
pmc: PMC6727926
doi:

Substances chimiques

Anticoagulants 0
Factor Xa Inhibitors 0
Fibrinolytic Agents 0
Vitamin K 12001-79-5
Warfarin 5Q7ZVV76EI
Rivaroxaban 9NDF7JZ4M3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2469-2476

Références

J Am Heart Assoc. 2018 Apr 13;7(8):
pubmed: 29654196
Arch Intern Med. 2007 Jan 8;167(1):68-73
pubmed: 17210880
Br J Clin Pharmacol. 2016 Mar;81(3):569-78
pubmed: 26493768
Int J Cardiol. 2018 Jun 15;261:78-83
pubmed: 29559181
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Stroke. 2017 Aug;48(8):2142-2149
pubmed: 28655814
J Am Heart Assoc. 2018 Apr 5;7(8):
pubmed: 29622587
Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):194-200
pubmed: 30395375
Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:41-9
pubmed: 22262592
Thromb Res. 2018 May 17;167:113-118
pubmed: 29803981
Am J Epidemiol. 2011 Jun 15;173(12):1404-13
pubmed: 21602301
Br J Clin Pharmacol. 2017 Sep;83(9):2056-2065
pubmed: 28345154
Circulation. 2015 Sep 29;132(13):1252-60
pubmed: 26199338
Arch Intern Med. 1987 Sep;147(9):1561-4
pubmed: 3632164
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
J Am Coll Cardiol. 2018 Jul 31;72(5):477-485
pubmed: 30049307
Int J Cardiol. 2018 Oct 1;268:113-119
pubmed: 29934230
Lancet Haematol. 2015 Apr;2(4):e150-9
pubmed: 26687957
Med Care. 2016 Feb;54(2):188-94
pubmed: 26683778
Eur J Clin Pharmacol. 2013 Mar;69(3):549-57
pubmed: 22763756
Eur Neurol. 2015;74(1-2):92-9
pubmed: 26337650
Am J Cardiol. 2017 Nov 15;120(10):1813-1819
pubmed: 28864318
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790
pubmed: 28595692
Fundam Clin Pharmacol. 2015 Dec;29(6):586-91
pubmed: 26301735
J Thromb Haemost. 2011 Nov;9(11):2153-8
pubmed: 21920015
BMJ. 2004 Jul 3;329(7456):15-9
pubmed: 15231615
Stat Sci. 2010 Feb 1;25(1):1-21
pubmed: 20871802
BMJ. 2017 Feb 10;356:j510
pubmed: 28188243
Am Heart J. 2008 Nov;156(5):855-63, 863.e2
pubmed: 19061698
Epidemiology. 2009 Jul;20(4):512-22
pubmed: 19487948
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001927
pubmed: 16034869
Epidemiology. 2017 Mar;28(2):237-248
pubmed: 27779497
J Intern Med. 2018 Jan;283(1):45-55
pubmed: 28861925
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Br J Clin Pharmacol. 2019 Feb;85(2):432-441
pubmed: 30423205
Pharmacotherapy. 2018 Jan;38(1):6-18
pubmed: 29028119
BMJ. 2016 Jun 16;353:i3189
pubmed: 27312796
J Am Heart Assoc. 2016 Jun 13;5(6):
pubmed: 27412905
Clin Pharmacol Ther. 2019 Jun;105(6):1439-1455
pubmed: 30499605
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354

Auteurs

Patrick Blin (P)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).

Laurent Fauchier (L)

Hôpital Trousseau-CHU de Tours, Service de cardiologie, Faculté de Médecine, Université François Rabelais, France (L.F.).

Caroline Dureau-Pournin (C)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).

Frédéric Sacher (F)

IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université/Bordeaux University Hospital (CHU), Electrophysiology and Ablation Unit, Centre de recherche Cardio-Thoracique de Bordeaux, INSERM U1045, Université de Bordeaux, France (F.S.).

Jean Dallongeville (J)

Institut Pasteur de Lille, Inserm U744, Unité d'Epidémiologie et de Santé Publique, France (J.D.).

Marie-Agnès Bernard (MA)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).

Regis Lassalle (R)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).

Cécile Droz-Perroteau (C)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).

Nicholas Moore (N)

From the Bordeaux PharmacoEpi, INSERM CIC1401, CHU de Bordeaux, Université de Bordeaux, France (P.B., C.D.-P., M.-A.B., R.L., C.D.-P., N.M.).
INSERM U1219, Université de Bordeaux, France (N.M.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH